Ausgabe 3/2013
Inhalt (36 Artikel)
A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production
Durvanei Augusto Maria, Jean Gabriel de Souza, Katia L. P. Morais, Carolina Maria Berra, Hamilton de Campos Zampolli, Marilene Demasi, Simone Michaela Simons, Renata de Freitas Saito, Roger Chammas, Ana Marisa Chudzinski-Tavassi
A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [18F]fluorothymidine-positron emission tomography
Seung Jin Lee, Eun Jung Kim, Haeng Jung Lee, Seog Young Kim, Seung Jun Oh, Jin Sook Ryu, Dae Hyuk Moon, Jin-Hee Ahn, Sang-We Kim
Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab
Ch. Gialeli, A. D. Theocharis, D. Kletsas, G. N. Tzanakakis, N. K. Karamanos
Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells
Amna Ali, Tatyana S. Sidorova, Diane F. Matesic
The novel antiangiogenic VJ115 inhibits the NADH oxidase ENOX1 and cytoskeleton-remodeling proteins
Amudhan Venkateswaran, David B. Friedman, Alexandra J. Walsh, Melissa C. Skala, Soumya Sasi, Girish Rachakonda, Peter A. Crooks, Michael L. Freeman, Konjeti R. Sekhar
Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways
Patrick T. Grogan, Kristina D. Sleder, Abbas K. Samadi, Huaping Zhang, Barbara N. Timmermann, Mark S. Cohen
EGFR and HER2 inhibition in pancreatic cancer
Naomi Walsh, Susan Kennedy, AnneMarie Larkin, Brendan Corkery, Lorraine O’Driscoll, Martin Clynes, John Crown, Norma O’Donovan
Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines
Brigette B. Y. Ma, Vivian W. Y. Lui, Connie W. C. Hui, Cecilia P. Y. Lau, Chi-Hang Wong, Edwin P. Hui, Margaret H. Ng, S. W. Tsao, Yan Li, Anthony T. C. Chan
Characterization of a membrane-active anti-tumor agent, UA8967
Robert T. Dorr, Betty K. Samulitis, Lee Wisner, Haiyong Han, Yu Zhao, Paul Beroza, Komath Damodaran, Suzu Igarashi, Terry H. Landowski, Daniel D. Von Hoff
Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system
Jenny Felth, Karolina Lesiak-Mieczkowska, Padraig D’Arcy, Caroline Haglund, Joachim Gullbo, Rolf Larsson, Stig Linder, Lars Bohlin, Mårten Fryknäs, Linda Rickardson
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer
Yoshikazu Hasegawa, Isamu Okamoto, Ken Takezawa, Masaaki Miyazaki, Junji Tsurutani, Kimio Yonesaka, Ryotaroh Morinaga, Asuka Tsuya, Masaaki Terashima, Toshihiro Kudoh, Koichi Azuma, Takayasu Kurata, Tatsuyuki Nishikawa, Masahiro Fukuoka, Yasumasa Nishimura, Kazuhiko Nakagawa
Metabolism of patupilone in patients with advanced solid tumor malignancies
Kevin R. Kelly, Markus Zollinger, Frédéric Lozac’h, Eugene Tan, Alain Mita, Felix Waldmeier, Patrick Urban, Suraj Anand, Yanfeng Wang, Piet Swart, Chris Takimoto, Monica Mita
A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel
Yong Sang Hong, Kyu-pyo Kim, Hyeong-Seok Lim, Kyun-Seop Bae, Min-Hee Ryu, Jae-Lyun Lee, Heung Moon Chang, Yoon-Koo Kang, Hyeyoun Kim, Tae Won Kim
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors
Christophe Massard, Jane Margetts, Nadia Amellal, Yvette Drew, Ratislav Bahleda, Peter Stevens, Jean Pierre Armand, Hilary Calvert, Jean Charles Soria, Cinthya Coronado, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Carlos Fernández-Teruel, Ruth Plummer
A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers
A. F. Baker, K. N. Adab, N. Raghunand, H. H. S. Chow, S. P. Stratton, S. W. Squire, M. Boice, L. A. Pestano, D. L. Kirkpatrick, T. Dragovich
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas
Tanja Trarbach, Marta Przyborek, Norbert Schleucher, Steffen Heeger, Christian Lüpfert, Udo Vanhoefer
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics
Nwabundo Nwankwo, Zhe Zhang, Ting Wang, Connie Collins, Lee Resta, Sabine Ermisch, Jeannette Day, Rodney Decker, Lori Kornberg, Steven Nicol, Donald Thornton, Deborah K. Armstrong, Michael A. Carducci
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
J. T. Hartmann, C. Kollmannsberger, I. Cascorbi, F. Mayer, M. M. Schittenhelm, S. Heeger, C. Bokemeyer
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
Gary Hudes, Scott T. Tagawa, Young E. Whang, Ming Qi, Xiang Qin, Thomas A. Puchalski, Manjula Reddy, Mark Cornfeld, Mario Eisenberger
Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study
Hajime Asahina, Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Yosuke Tamura, Kazunori Honda, Yoshitaka Seki, Yuko Tanabe, Hitoshi Shimada, Xiaojin Shi, Tomohide Tamura
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Amir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, Lai Wei, Mitch A. Phelps, Zhongfa Liu, Erica J. Harper, S. Percy Ivy, Xin Wu, Bing-Sen Zhou, Xiyong Liu, Deidre Deam, J. Paul Monk, William J. Hicks, Yun Yen, Gregory A. Otterson, Michael R. Grever, Tanios Bekaii-Saab
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors
Don G. Morris, Xiaolan Feng, Lisa M. DiFrancesco, Kevin Fonseca, Peter A Forsyth, Alexander H. Paterson, Matt C. Coffey, Brad Thompson
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
Andrea Wang-Gillam, Stacey Plambeck-Suess, Peter Goedegebuure, Peter O. Simon, Jonathan B. Mitchem, John R. Hornick, Steven Sorscher, Joel Picus, Rama Suresh, Albert C. Lockhart, Benjamin Tan, Williams G. Hawkins
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors
Michael S. Gordon, Lee S. Rosen, David Mendelson, Ramesh K. Ramanathan, Jonathan Goldman, Lili Liu, Yan Xu, Stanton L. Gerson, Stephen P. Anthony, William D. Figg, Shawn Spencer, Bonne J. Adams, Charles P. Theuer, Bryan R. Leigh, Glen J. Weiss
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction
J. P. Delord, A. Ravaud, J. Bennouna, P. Fumoleau, S. Favrel, M. C. Pinel, P. Ferré, F. Saliba
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
A. H. Awada, H. Dumez, A. Hendlisz, P. Wolter, T. Besse-Hammer, M. Uttenreuther-Fischer, P. Stopfer, F. Fleischer, M. Piccart, P. Schöffski
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors
Geoffrey I. Shapiro, Stewart McCallum, Laurel M. Adams, Laurie Sherman, Steve Weller, Suzanne Swann, Harold Keer, Dale Miles, Thomas Müller, Patricia LoRusso
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
Maja J. A. de Jonge, Paul Hamberg, Jaap Verweij, Shawna Savage, A. Benjamin Suttle, Jeffrey Hodge, Thangam Arumugham, Lini N. Pandite, Herbert I. Hurwitz
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers, Boris Alekseev, Mikhail Shkolnik, Simon J. Crabb, Susan Li, Shobha Seetharam, Thomas A. Puchalski, Chris Takimoto, Yusri Elsayed, Fitzroy Dawkins, Johann S. de Bono
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma
Tara C. Gangadhar, Joseph I. Clark, Theodore Karrison, Thomas F. Gajewski
Determinants of patient screen failures in Phase 1 clinical trials
Alexandra Mckane, Chao Sima, Ramesh K. Ramanathan, Gayle Jameson, Cathy Mast, Erica White, Sharon Fleck, Molly Downhour, Daniel D. Von Hoff, Glen J. Weiss
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1
Erika Rimondi, Paola Secchiero, Elisabetta Melloni, Vittorio Grill, Giorgio Zauli
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis
Alyssa Fischer, Shenhong Wu, Alan L. Ho, Mario E. Lacouture
Erratum to: Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study
Hajime Asahina, Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Yosuke Tamura, Kazunori Honda, Yoshitaka Seki, Yuko Tanabe, Hitoshi Shimada, Xiaojin Shi, Tomohide Tamura
Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors
Christophe Massard, Jane Margetts, Nadia Amellal, Yvette Drew, Ratislav Bahleda, Peter Stephens, Jean Pierre Armand, Hilary Calvert, Jean Charles Soria, Cinthya Coronado, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Carlos Fernández-Teruel, Ruth Plummer
Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA
Serena Marchetti, Dick Pluim, Monique van Eijndhoven, Olaf van Tellingen, Roberto Mazzanti, Jos H. Beijnen, Jan H. M. Schellens